You are leaving Medscape Education

Cancel Continue

CME & Education

Return to Activity

Return to Activity: Winter Conference Forecast for CLL and MCL: An Expert Exchange on Bruton Tyrosine Kinase Inhibitors

CME/CE Test

Winter Conference Forecast for CLL and MCL: An Expert Exchange on Bruton Tyrosine Kinase Inhibitors

Which of the following statements reflects the efficacy results of the phase 3 ALPINE study investigating zanubrutinib vs ibrutinib in patients with R/R CLL/SLL?

Ibrutinib is superior to zanubrutinib in both ORR and PFS

Ibrutinib is superior to zanubrutinib in ORR, but not in PFS

Zanubrutinib is superior to ibrutinib in both ORR and PFS

Zanubrutinib is superior to ibrutinib in ORR, but not in PFS
In the investigated-initiated multicenter TARMAC study investigating time-limited ibrutinib and tisagenlecleucel (tisa-cel) in patients with R/R mantle cell lymphoma, what was the achieved ORR?

90%

80%

70%

60%